Do you consider adjuvant chemotherapy in a patient who has received ddMVAC preoperatively and had pT3pN2 disease at time of surgery?

Community
Company
News
Contact Us
Sign in

Topics: Genitourinary Cancers • Bladder Cancer • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

No. There is no high level evidence of doing that. I would strongly favor clinical trial, e.g. AMBASSADOR is accruing (or active surveillance if no trial available).

6349

Related Questions

Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?

How would you treat a patient with metastatic urothelial carcinoma with early progression on maintenance immunotherapy?

Is bilateral hearing loss requiring hearing aids an absolute or relative contraindication for neoadjuvant cisplatin in MIBC?

Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?

Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?

Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?

Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?

In what situations would you recommend neoadjuvant chemotherapy prior to chemo/RT when pursuing bladder preservation in locally advanced bladder cancer?

Based on the VESPER trial data, do you recommend the full 6 cycles or 3-4 cycles of ddMVAC for neoadjuvant muscle invasive bladder cancer treatment?

Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?